Bone Biologics Corp
BBLG · XNASCIK 1419554fmd_0X2MXD6T1CQ6K6C6VZPTQ3JKEGManufacturing · Orthopedic, Prosthetic & Surgical Appliances & SuppliesTemplate: Standard
Coverage: Jan 01, 2005 to Sep 30, 2026, 80 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1,070 | – | – | 1,070 | 1,070 | – | – | – | – | – |
| Net interest income | – | – | – | – | – | – | – | 0 | – | – |
| Research and development | 10 | 1 | 0 | 1 | 0 | 0 | 2 | 7 | 2 | 1 |
| Total operating expenses | 20 | 3 | 3 | 2 | 1 | 1 | 4 | 9 | 4 | 3 |
| Operating income | (20) | (3) | (3) | (2) | (1) | (1) | (4) | (9) | (4) | (3) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (5) | (4) | (2) | (1) | (1) | (1) | 2 | 0 | 0 | 0 |
| Income before taxes | (26) | (7) | (4) | (3) | (2) | (2) | – | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – |
| Net income from continuing operations | (26) | (7) | (4) | (3) | (2) | (2) | – | – | – | – |
| Net income | (26) | (7) | (4) | (3) | (2) | (2) | (1) | (9) | (4) | (3) |
| Net income to common shareholders | – | – | – | – | – | – | – | (9) | (7) | (3) |